Published in BMC Infect Dis on November 12, 2012
Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control. World J Gastroenterol (2015) 0.87
Rapid Virological Response Represents the Highest Prediction Factor of Response to Antiviral Treatment in HCV-Related Chronic Hepatitis: a Multicenter Retrospective Study. Hepat Mon (2015) 0.81
Predictive factors for sustained virological response after treatment with pegylated interferon α-2a and ribavirin in patients infected with HCV genotypes 2 and 3. PLoS One (2014) 0.80
Towards HCV extinction with modern HCV treatment? "Yes we can!". BMC Infect Dis (2012) 0.76
A double-blind randomized controlled study to evaluate the efficacy of low-dose oral interferon-alpha in preventing hepatitis C relapse. J Interferon Cytokine Res (2013) 0.75
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol (2011) 6.63
Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology (2012) 2.35
Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology (2012) 1.95
New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut (2012) 1.50
Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology (2012) 1.35
Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin. Hepatology (2012) 1.19
Informed deferral: a moral requirement for entry into the hepatitis C virus treatment warehouse. Hepatology (2012) 0.87
Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology (2002) 5.71
Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol (2008) 3.50
Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients. J Hepatol (2013) 3.20
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol (2005) 3.10
Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations. Hepatology (2012) 3.04
Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis c virus genotype 1. Hepatology (2008) 2.91
Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis. Hepatology (2009) 2.87
Herbal hepatotoxicity: a hidden epidemic. Intern Emerg Med (2012) 2.69
Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology (2014) 2.47
Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol (2004) 2.30
Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology (2006) 1.92
Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol (2007) 1.73
A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology (2010) 1.64
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology (2004) 1.52
Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) - lack of interference by iron deposition. Br J Haematol (2009) 1.49
IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. J Hepatol (2012) 1.48
Fecal calprotectin in clinical practice: a noninvasive screening tool for patients with chronic diarrhea. J Clin Gastroenterol (2012) 1.44
Serology in adults with celiac disease: limited accuracy in patients with mild histological lesions. Intern Emerg Med (2011) 1.43
Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology (2004) 1.42
Halitosis: could it be more than mere bad breath? Intern Emerg Med (2010) 1.40
Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology (2012) 1.35
Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol (2008) 1.28
Endemic hepatitis C virus infection in a Sicilian town: further evidence for iatrogenic transmission. J Med Virol (2002) 1.20
Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood (2010) 1.17
Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C. Haematologica (2008) 1.15
Oxidative stress inhibits IFN-alpha-induced antiviral gene expression by blocking the JAK-STAT pathway. J Hepatol (2006) 1.12
HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin. J Hepatol (2004) 1.08
Anti-tissue transglutaminase antibodies in patients with abnormal liver tests: is it always coeliac disease? Am J Gastroenterol (2005) 1.06
Current and future HCV therapy: do we still need other anti-HCV drugs? Liver Int (2015) 1.06
Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Clin Pract Gastroenterol Hepatol (2009) 1.06
Transglutaminase type II plays a protective role in hepatic injury. Am J Pathol (2003) 1.06
Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. J Hepatol (2005) 1.04
Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study. World J Hepatol (2012) 1.04
Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. Dig Liver Dis (2013) 1.02
Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. Hepatology (2010) 1.02
IL-10 and TNF-alpha polymorphisms and the recovery from HCV infection. Hum Immunol (2003) 1.01
Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. Antivir Ther (2012) 1.01
IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. Haematologica (2011) 1.00
Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. Hepatology (2013) 0.99
Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible? Liver Int (2014) 0.97
Cardiovascular diseases and HCV infection: a simple association or more? Gut (2013) 0.97
Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. Liver Int (2011) 0.97
Recent progress and new trends in the treatment of hepatitis B. J Med Virol (2002) 0.96
Extrahepatic manifestations of hepatitis C virus infection. Clin Liver Dis (2008) 0.95
Optimizing the treatment of chronic hepatitis due to hepatitis C virus genotypes 2 and 3: a review. Liver Int (2009) 0.95
Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: is the serum hepatitis B virus profile reliable? Liver Int (2009) 0.93
Implication of normal liver enzymes in liver disease. J Viral Hepat (2009) 0.93
Hyperferritinemia is a risk factor for steatosis in chronic liver disease. World J Gastroenterol (2009) 0.92
Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: a meta-analysis. J Hepatol (2009) 0.91
HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy. Antivir Ther (2005) 0.90
Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection. Antivir Ther (2009) 0.89
Hepatitis C and diabetes: the inevitable coincidence? Expert Rev Anti Infect Ther (2009) 0.89
PNPLA3 GG genotype and carotid atherosclerosis in patients with non-alcoholic fatty liver disease. PLoS One (2013) 0.88
Inverse correlation between plasma oxysterol and LDL-cholesterol levels in hepatitis C virus-infected patients. Dig Liver Dis (2011) 0.88
Phylogenetic reconstruction of HCV genotype 1b dissemination in a small city centre: the Camporeale model. J Med Virol (2008) 0.88
The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver Int (2014) 0.88
Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C. J Hepatol (2013) 0.87
Hepatocellular cancer: optimal strategies for screening and surveillance. Dig Dis (2009) 0.87
How to optimize HCV therapy in genotype 1 patients: predictors of response. Liver Int (2013) 0.86
High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis. Dig Liver Dis (2011) 0.86
Effects of IL28B rs12979860 CC genotype on metabolic profile and sustained virologic response in patients with genotype 1 chronic hepatitis C. Clin Gastroenterol Hepatol (2012) 0.85
Expansion of intestinal CD4+CD25(high) Treg cells in patients with ankylosing spondylitis: a putative role for interleukin-10 in preventing intestinal Th17 response. Arthritis Rheum (2010) 0.85
Needle track seeding following percutaneous procedures for hepatocellular carcinoma. World J Hepatol (2009) 0.85
Intrahepatic IgG/IgM plasma cells ratio helps in classifying autoimmune liver diseases. Dig Liver Dis (2010) 0.85
Should cirrhosis change our attitude towards treating non-hepatic cancer? Liver Int (2011) 0.85
HCV genotypes in Sicily: is there any evidence of a shift? J Med Virol (2009) 0.84
Treatment of hepatitis C: critical appraisal of the evidence. Expert Opin Pharmacother (2005) 0.83
Survival of patients with hepatocellular carcinoma (HCC) treated by percutaneous radio-frequency ablation (RFA) is affected by complete radiological response. PLoS One (2013) 0.83
Inguinal hernioplasty improves the quality of life in patients with cirrhosis. Am J Surg (2008) 0.83
Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients. Antivir Ther (2009) 0.83
CT enterography as a powerful tool for the evaluation of inflammatory activity in Crohn's disease: relationship of CT findings with CDAI and acute-phase reactants. Radiol Med (2014) 0.83
Serum γ-glutamyl transferase levels, insulin resistance and liver fibrosis in patients with chronic liver diseases. PLoS One (2012) 0.82
Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen? J Hepatol (2007) 0.82
Preoperative and postoperative radiotherapy and survival in colorectal cancer. Lancet (2002) 0.82
Chronic hepatitis B: who to treat and which choice of treatment? Expert Rev Anti Infect Ther (2009) 0.82
Optimal therapy in hepatitis C virus genotypes 2 and 3 patients. Liver Int (2011) 0.82
Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment. J Med Virol (2006) 0.82
Fibrosis in chronic viral hepatitis. Best Pract Res Clin Gastroenterol (2011) 0.81
Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy. J Med Econ (2015) 0.81
Virological profiles in patients with chronic hepatitis C and overt or occult HBV infection. Am J Gastroenterol (2002) 0.81
Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial. World J Gastroenterol (2006) 0.81
Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop. Dig Liver Dis (2011) 0.81
Oesophagogastroduodenoscopy in patients with cirrhosis: Extending the range of detection beyond portal hypertension. Dig Liver Dis (2010) 0.80
Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age? Expert Rev Anticancer Ther (2013) 0.80
Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. Liver Int (2012) 0.79
Parvovirus B19 and "cryptogenic" chronic hepatitis. J Hepatol (2003) 0.79
The hepatic expression of vitamin D receptor is inversely associated with the severity of liver damage in genotype 1 chronic hepatitis C patients. J Clin Endocrinol Metab (2015) 0.79
Liver stiffness measurement by transient elastography predicts early recovery from acute hepatitis. Gut (2010) 0.79
Expression of cytokeratin 7 and 20 in pathological conditions of the bile tract. Pathol Res Pract (2003) 0.79
NT pro BNP plasma level and atrial volume are linked to the severity of liver cirrhosis. PLoS One (2013) 0.79
Hepatitis C in the elderly: a multicentre cross-sectional study by the Italian Association for the Study of the Liver. Dig Liver Dis (2012) 0.79
Osteodystrophy in chronic liver diseases. Intern Emerg Med (2012) 0.78
No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study. Clin Exp Rheumatol (2012) 0.78
Non invasive indexes for the assessment of patients with non-alcoholic fatty liver disease. Curr Pharm Des (2013) 0.78
Liver follicular helper T-cells predict the achievement of virological response following interferon-based treatment in HCV-infected patients. Antivir Ther (2012) 0.78
Acute hepatitis C: in search of the optimal approach to cure. Hepatology (2006) 0.77
Assessment by Fibroscan of fibrosis in nonalcoholic fatty liver disease: XL versus M probe? Hepatology (2012) 0.77
The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach. Curr Pharm Des (2004) 0.77